Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

Jahr

2013

Autoren

Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, Stüve O, Rieckmann P, Montalban X, Ziemssen T, Auberson LZ, Pohlmann H, Mercier F, Dahlke F, Wallström E.

Verlag

Lancet Neurol. 2013 Aug;12(8):756-67. Epub 2013 Jun 11. Erratum in: Lancet Neurol. 2013 Sep;12(9):846.

Link

https://doi.org/10.1016/s1474-4422(13)70102-9

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

MS brain health quality standards: a survey on the reality in clinical practice in Germany

Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study

Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study

Eculizumab Use in Neuromyelitis Optica Spectrum Disorders

Long-term effects of siponimod on cardiovascular and autonomic nervous system in secondary progressive multiple sclerosis